Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Smart Artificial Beta Cells Could Lead to New Diabetes Treatment

October 31, 2017 By University of North Carolina Health Care

This is a fluorescence image of the artificial beta cells. (Credit: Gu Lab, UNC-NC State)

Treating type 1 diabetes and some cases of type 2 diabetes has long required painful and frequent insulin injections or a mechanical insulin pump for insulin infusion. But researchers from the University of North Carolina and NC State have now developed what could be a much more patient-friendly option: artificial cells that automatically release insulin into the bloodstream when glucose levels rise.

These “artificial beta cells” (ABCs) mimic the functions of the body’s natural glucose-controllers, the insulin-secreting beta cells of the pancreas. The loss or dysfunction of these cells causes type 1 diabetes and many cases of type 2 diabetes. The idea is that the AβCs could be subcutaneously inserted into patients, which would be replaced every few days, or by a painless and disposable skin patch.

As the researchers report in Nature Chemical Biology, a single injection of the ABCs into diabetic mice lacking beta cells quickly normalized the animals’ blood glucose levels and kept those levels normal for up to five days.

“Our plan now is to further optimize and test these synthetic cells in larger animals, develop a skin patch delivery system for them, and ultimately test them in people with diabetes,” said principal investigator Zhen Gu, PhD, a professor in the Joint UNC/NC State Department of Biomedical Engineering. Gu also holds appointments in the UNC School of Medicine, the UNC Eshelman School of Pharmacy, and the UNC Diabetes Care Center.

At least six million people in the United States use insulin as a diabetes treatment, either by injection or a mechanical pump. So far, delivered insulin in pill form has been challenging because it’s a large molecule that would be destroyed by digestive enzymes and acids before it could reach the bloodstream.

The major problem with current insulin treatments, however, is not that they can’t be delivered in a pill, but that they can’t control blood glucose levels automatically and efficiently, as normal insulin-secreting pancreatic cells do. Transplants of pancreatic cells can solve that problem in some cases. However, such cell transplants are expensive, require donor cells that are often in short supply, require immune-suppressing drugs, and often fail due to the destruction of the transplanted cells.

Gu and colleagues have been researching solutions to the insulin-delivery problem for much of the past decade. For this project, they adopted a particularly ambitious approach: making artificial cells that, to a great extent, do what natural pancreatic beta cells do.

Gu’s ABCs are constructed with a simplified version of a normal cell’s two-layered lipid membrane. The key innovation is what these cells contain: specially designed, insulin-stuffed vesicles. A rise in blood glucose levels leads to chemical changes in the vesicle coating, causing the vesicles to start fusing with the ABC’s outer membrane – thus releasing the insulin payloads.

“This is the first demonstration using such a vesicle fusion process for delivering insulin that employs insulin-containing vesicles like those found in a beta cell and can reproduce the beta cell’s functions in sensing glucose and responding with insulin ‘secretion’,” said Zhaowei Chen, PhD, a lead author and postdoctoral researcher in Gu’s lab.

The ABCs showed a rapid responsiveness to excess glucose levels in lab-dish tests and in diabetic mice without beta cells. “The mice went from hyperglycemic to normoglycemic within an hour, and they remained normoglycemic for up to five days after that,” Gu said.

Control mice injected with no-insulin ABCs remained hyperglycemic.

Gu and colleagues plan further preclinical tests and expect to develop a method for delivering the cells painlessly via a skin patch that could be simply replaced.

Co-author John Buse, MD, PhD, the Verne S. Caviness Distinguished Professor at UNC, chief of the division of endocrinology, and director of the UNC Diabetes Care Center, said, “There is still much work needed to optimize this artificial-cell approach before human studies are attempted, but these results so far are a remarkable, creative first step to a new way to solve the diabetes problem using chemical engineering as opposed to mechanical pumps or living transplants.” Gu and his team are also working separately on a cell-free skin patch, a “smart insulin patch” that senses blood glucose levels and secretes insulin into the bloodstream as needed.

Related Articles Read More >

A photo of Medtronic's Symplicity Spyral renal denervation catheter with a gloved hand for scale.
With Medtronic’s next-gen RDN devices and procedures advancing, Project Galileo is next
MIT emergency drug delivery implantable device glucagon diabetes (1)
Implantable device could save diabetes patients from dangerously low blood sugar
An illustration of the Endogenex ReCET system inside a patient.
This minimally invasive diabetes device delivers pulsed field energy in the gut
UCSD diabetic kidney disease.
New imaging technology offers noninvasive 3D view of diabetic kidney disease
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe